Dermatology

Carrington Provides Update on Its EquineVet Acemannan Advanced Wound Therapy

Published in Medical Letter on the CDC and FDA, April 22nd, 2007

Carrington Laboratories, Inc. (NASDAQ:CARN) announced that seven (7) seasoned professional representatives with experience in equine product sales now support the Carrington(R) EquineVet(TM) advanced wound care product line. Clinical results demonstrate usefulness of products to equine veterinarians and horse owners.

The EquineVet(TM) line contains a core component in Carrington's injectable biologic product, Acemannan Immunostimulant(TM) (AI), marketed under authorization from the United States Department of Agriculture (USDA), for the treatment of fibrosarcoma (a form of soft tissue cancer) in cats and dogs. AI has a polymeric backbone of acetylated mannan called...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2007-04-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry